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A B S T R A C T
Introduction: The correction of metabolic acidosis caused by renal failure is achieved by adding 
bicarbonate during dialysis. In order to avoid the precipitation of calcium carbonate and 
magnesium carbonate that takes place in the dialysis fluid (DF) when adding bicarbonate, 
it is necessary to add an acid, usually acetate, which is not free of side effects. Thus, citrate 
appears as an advantageous alternative to acetate, despite the fact that its acute effects are 
not accurately known.
Objective: To assess the acute effect of a dialysis fluid containing citrate instead of acetate 
on acid-base balance and calcium-phosphorus metabolism parameters.
Material and methods: A prospective crossover study was conducted with twenty-four patients 
(15 male subjects and 9 female subjects). All patients underwent dialysis with AK-200-Ultra-S 
monitor with SoftPac® dialysis fluid, made with 3 mmol/L of acetate and SelectBag Citrate®, 
with 1 mmol/L of citrate and free of acetate. The following were measured before and after 
dialysis: venous blood gas monitoring, calcium (Ca), ionic calcium (Cai), phosphorus (P) and 
parathyroid hormone (PTH).
Results: Differences (p<0.05) were found when using the citrate bath (C) compared to acetate 
(A) in the postdialysis values of: pH, C: 7.43 (0.04) vs. A: 7.47 (0.05); bicarbonate, C: 24.7 (2.7) vs. 
A: 27.3 (2.1) mmol/L; base excess (BEecf), C: 0.4 (3.1) vs. A: 3.7 (2.4) mmol/L; corrected calcium 
(Cac), C: 9.8 (0.8) vs. A: 10.1 (0.7) mg/dL; and Cai, C: 1.16 (0.05) vs. A: 1.27 (0.06) mmol/L. No 
differences were found in either of the parameters measured before dialysis.
Conclusion: Dialysis with citrate provides better control of postdialysis acid-base balance, 
decreases/avoids postdialysis alkalaemia, and lowers the increase in Cac and Cai. This finding 
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From a technical point of view, in order to avoid precipita-
tion of calcium carbonate and magnesium carbonate that 
takes place in the DF when adding bicarbonate, it is necessary 
to add an acid. Thus, a DF generation system is used with 2 
concentrates: one with bicarbonate and the other with acid. 
Acetic acid is most generally used, at concentrations ranging 
from 3 to 10 mmol/L. This small amount causes an acetate 
transfer to the patient during HD, increasing its blood con-
centration, since the DF has concentrations which are 30 to 
40 times greater than the normal blood values (0.1 mmol/L). 
This exposure to acetate increases in online haemodiafiltra-
tion (HDF) techniques3. due to the higher amount of infused 
fluid. Among the side effects described with acetate, hemo-
dynamic instability caused by vasodilation mediated by nitric 
oxide release4 and the activation of proinflammatory cyto-
kines by hypoxia5 are worth mentioning due to their impor-
tance dur ing HD. Even compared to a DF with low 
concentrations of acetate (3 mmol/L), a lower risk of haemo-
dynamic complications has been described when patients 
undergo dialysis with an acetate-free DF6.
Introduction
The correction of metabolic acidosis is one of the treatment 
goals for chronic kidney disease. To achieve so in patients 
who are undergoing haemodialysis, bicarbonate is added 
during the sessions. The optimal bicarbonate concentration 
these patients should maintain is not accurately known. The 
KDOQI guidelines recommend maintaining a predialysis 
bicarbonate of 22 mEq/L in all patients1, while the UK Renal 
Association suggests different targets for patients undergoing 
peritoneal dialysis (25-29 mmol/L) and haemodialysis (HD) 
(20-26 mmol/L)2.
We could define the optimal bicarbonate concentration of 
DF as that which prevents interdialysis metabolic acidosis 
and avoids intradialysis and postdialysis alkalosis. Achieving 
this goal is not an easy task, as patients who are undergoing 
haemodialysis have progressive bicarbonate depletion in the 
interdialysis period and a sudden bicarbonate overload takes 
place during dialysis.
is of special interest in patients with predisposing factors for arrhythmia and patients with 
respiratory failure, carbon dioxide retention, calcifications and advanced liver disease.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
under the terms of the CC BY-NC-ND Licence(http://creativecommons.org/licenses/
by-nc-nd/4.0).
Efecto agudo del baño con citrato sobre la alcalemia postdiálisis
R E S U M E N
Introducción: La corrección de la acidosis metabólica provocada por la insuficiencia renal se 
consigue aportando bicarbonato durante la diálisis. Para evitar la precipitación de carbonato 
cálcico y magnésico que se produce en el líquido de diálisis (LD) al añadir bicarbonato, es 
necesario añadir un ácido, habitualmente acetato, que no está exento de efectos secundarios. 
Así, el citrato se presenta como una alternativa ventajosa al acetato, aunque sus efectos 
agudos no se conocen con precisión.
Objetivo: Evaluar el efecto agudo sobre los parámetros del equilibrio ácido base y del 
metabolismo calcio-fósforo con la utilización de un líquido de diálisis con citrato en lugar 
de acetato. 
Material y métodos Estudio prospectivo y cruzado realizado en veinticuatro pacientes (15 
hombres y 9 mujeres). Todos los pacientes se dializaron con monitor AK- 200-Ultra-S con 
líquido de diálisis SoftPac®, elaborado con 3 mmol/l de acetato y con SelectBag Citrate®, con 
1 mmol/l de citrato, libre de acetato. Se extrajeron pre y post-diálisis: gasometría venosa, 
calcio (Ca), calcio iónico (Cai), fósforo (P) y hormona paratiroidea (PTH). 
Resultados Encontramos diferencias (p < 0,05) cuando utilizamos el baño con citrato (C) frente 
a acetato (A) en los valores postdiálisis de: pH (C: 7,43 (0,04) vs. A: 7,47 (0,05)), bicarbonato (C: 
24,7 (2,7) vs. A: 27,3 (2,1) mmol/L), exceso de base (BEecf) (C: 0,4 (3,1) vs A: 3,7 (2,4) mmol/L), 
calcio corregido (Cac) (C: 9,8 (0,8) vs A: 10,1 (0,7) mg/dl) y Cai (C: 1,16 (0,05) vs A: 1,27 (0,06) 
mmol/L). No encontramos diferencias en ninguno de los parámetros medidos prediálisis. 
Conclusión La diálisis con citrato consigue un mejor control de equilibrio ácido base postdiálisis 
disminuyendo/evitando la alcalemia postdiálisis y un menor aumento de Cac y Cai. Este 
hallazgo es de especial interés en pacientes con factores predisponentes a arritmias, pacientes 
con insuficiencia respiratoria, retención de carbónico, calcificaciones y hepatopatía avanzada.
© 2015 Sociedad Española de Nefrología. Publicado por ELSEVIER ESPAÑA, SLU. Publicado 
bajo los términos de la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0).
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mmol/L of citrate and free of acetate. The composition of the 
used dialysis fluids is shown in Table 1.
Each patient was his/her own control, and no modifica-
tions were made in the dialysis schedule or pharmacological 
treatment during the study; the standard work schedule was 
followed. The fluid calcium concentration used was higher in 
the DF containing citrate: 1.5 mmol/L in acetate fluid and 1.65 
mmol/L in the citrate fluid. Three K concentrations were used 
in the DF containing acetate (1.5, 2 and 3 mmol/L), which were 
the same the patients had before their enrolment in the study, 
and 2 mmol/L of K in the DF containing citrate.
Collected dialysis and demographic parameters
A set of demographic parameters were collected: age, under-
lying condition, weight, dialysis technique (HD or HDF), the 
type of vascular access (fistula [AVF] or catheter [CT]), and 
residual renal function (RRF), measured as mean urea and 
creatinine clearance ((CCr+CU)/2) in 24-hour urine (if this was 
< 1 mL/min or diuresis < 100 mL/day, absence of RRF was 
considered).
Dialysis parameters included: time, blood flow (Qb), dial-
ysis fluid flow (Qd), sodium and bicarbonate conductivities, 
fluid temperature, dialyser, heparin type and dose, HDF infu-
sion volumes, Kt automatically measured by the Diascan® 
biosensor, ultrafiltration (UF) per session, and blood pressure 
(BP) before and after HD. The number of hypotensive episodes 
was also recorded, which was defined as every acute decrease 
in blood pressure perceived by the patient which required the 
intervention of nursing personnel.
Laboratory tests
All blood samples were collected through the arterial line of 
the vascular access. The predialysis samples were collected 
immediately before starting the technique, and postdialysis 
samples were taken after reducing the Qb to 50 mL/min for 
60 seconds upon finishing the session.
Therefore, other acids have been researched for years as 
DF stabilisers. The first acetate substitution attempts involved 
hydrochloric acid. With this acetate-free DF, it was possible 
to observe that the usual increase in acetatemia shown by 
patients undergoing dialysis with DF containing bicarbonate 
and 4 mmol/L of acetate could be corrected by using a con-
centrate containing hydrochloric acid7,8. The problem with 
this DF with high chlorine content is that it modifies the 
sodium concentration-conductivity correlation, thus produc-
ing changes in serum ions so that it is necessary to change 
the total and partial conductivities of bicarbonate, despite the 
fact that its use has not been clearly standardised.
At present, we have a DF containing citrate, which appears 
as an alternative to acidification without using acetate. Citrate 
is a calcium (Ca) chelating agent that is used due to its anti-
coagulant effect by reducing ionic calcium (Cai). It is estimated 
to cause a 10% decrease in Cai; therefore, most authors rec-
ommend supplementing calcium contained in the DF when 
citrate is used as an acid to correct these differences. As 
shown by Steckiph et al.9, per each citrate mmol, the calcium 
concentration has to be increased 0.15 mmol/L to maintain 
the calcium balance during treatment and to prevent hypo-
calcaemia. Several long-term beneficial effects related to 
citrate have been described, such as a lower thrombogenic-
ity10, improvement in clearance11,12, inflammation13, nutri-
tion14, tolerance15,16and acid-base control with a lower 
predialysis acidosis17.
Objective
To assess the acute effect on acid-base balance and calci-
um-phosphorus metabolism parameters with the use of a DF 
containing citrate instead of acetate in patients with chronic 
HD.
Material and methods
The study followed a prospective, crossover design and was 
conducted at single hospital dialysis site.
Patients
Twenty-four clinically stable patients were enrolled (15 male 
and 9 female subjects). The inclusion criteria were age older 
than 18, having received dialysis treatment for more than 
three months, being clinically stable and giving an informed 
consent.
Methods
A prospective, crossover study was used to compare a single 
dialysis session with DF containing acetate to another dialy-
sis session with citrate. All patients underwent dialysis with 
AK-200-Ultra-S monitor with SoftPac® dialysis fluid, made 
with 3 mmol/L of acetate and with SelectBag Citrate®, with 1 
Table 1 – Calculated Electrolyte Composition of DF 
containing Acetate and DF containing Citrate
Dialysis fluids 
(mmol/L) 
Softpack G 
G 196a, G 295b, G 394c
Selectbag Citrate 
CX 265G
G 196a, G 295b, G 394c CX 265G
Na 140 140
K 1.5a, 2b y 3c 2
Ca 1,5 1.65
Mg 0.37a y 0.5b,c 0.5
Acetato 3 0
Citrato 0 1
Cl 108.2a, 109b, 110c 109.3
Glu (g/L) 1 1
Bicarbonato 34 34
Na: sodium; K: potassium; Ca: calcium; Mg: magnesium;  
Cl: chloride; Glu: glucose
 NEFROLOGIA 2015; 35(2):164-171 167
in 11 (45.8%) patients, with a mean infusion volume of 27.7 
(3.8) [20.8-33.9] litres.
Potassium concentrations used in DF containing acetate 
were 1.5, 2 and 3 mmol/L in 9 (37.5%), 12 (50%) and 3 (12.5%) 
patients, respectively.
Anticoagulation therapy was performed with heparin 
sodium at 1% in all patients except for one who used enoxa-
parin, with a mean heparin dose of 51.6 (18.5) [20-90] units.
The mean values of the analysed parameters are shown in 
Table 2. Statistically significant differences were found when 
using the citrate bath compared to acetate in the following 
postdialysis values: pH, bicarbonate, BEef, K, Cac and Cai. No 
differences were found in any of the predialysis values, or in 
Blood tests included
• Acid-base parameters by means of venous blood gas mon-
itoring that included pH, partial pressure of carbon dioxide 
(PCO2), partial pressure of oxygen (PO2), bicarbonate, base 
excess of the extracellular fluid (BEecf), measured oxygen 
saturation (sO2m).
• Biochemical parameters: sodium (Na), potassium (K), mag-
nesium (Mg), Ca, Cai, phosphorus (P), and parathyroid hor-
mone (PTH)
The pH was determined by potentiometry, pCO2 by 
Severinghaus electrode, pO2 by amperometry and Cai by 
ion-selective electrode (ISE). Biochemical determinations 
were made with an autoanalyser (ADVIA® 2400 Chemistry 
System, Bayer). PTH determinations were made by chemilu-
minescence with the Bayer ADVIA CENTAUR system.
Ca concentration was corrected for pH (Cac) using the fol-
lowing formula: 
Cac = measured Ca × [1-0.53 × (7.40 – measured pH)]
Statistical analysis
The statistical analysis was conducted via the SPSS 15.0 pro-
gramme (SPSS INC., Chicago IL, USA). Descriptive data were 
expressed as arithmetic mean and standard deviation (SD).
For the comparison of two independent continuous vari-
ables, the Student’s t-test was used for paired samples. For 
the comparison of more than two quantitative variables, the 
ANOVA test was used. A p <0.05 was considered statistically 
significant.
Results
Mean age of the twenty-four patients was 68.13 (19.2) (range 
19-92) years. Dry weight was 72.7 (20.5) Kg. Renal failure aeti-
ologies were as follows: glomerulonephritis (n = 8), interstitial 
nephritis (n = 3), polycystosis (n = 1), vascular (n = 3), diabetes 
mellitus (n = 2), and unknown (n = 7). Ten (41.7%) patients had 
RRF, with (CCr+CU)/2 of 6.5 (3.2) [2.7-14.4] mL/min. Six of them 
underwent dialysis twice weekly (25%). This is the frequency 
with which we usually administer dialysis if the patient 
meets the following requirements: (CCr+CU)/2 ≥ 5 mL/min, 
normal blood pressure, adequate P and volume control. 
Eighteen (75%) patients underwent dialysis through an arte-
riovenous fistula and 6 (25%) by catheter. Thirteen (54.2%) 
patients underwent dialysis with high-flow HD and 11 (45.8%) 
with HDF. Mean dialysis time was 250 (16) [210-270] minutes. 
All patients had individualised bicarbonate concentrations: 
30.8 (2.4) [26-34] mmol/L, sodium conductivity: 13.8 (0.1) [13.7-
14.1] mS/cm and DF temperature: 35.8 (0.4) [35-36.5] ºC.
All patients were informed about the study characteristics 
and gave their consent to participate in the study.
Dialysers were the same and were distributed as follows: 
5 (21%) polyethersulfone of 1.8 m2 (Xenium®), 8 (33%) helixone 
of 1.8 m2 ([FX-class]® 80 and 800) and 11 (46%) polyamide of 
2.1 m2 (Poliflux® 210H). The HDF technique was implemented 
Table 2 – Results of mean values of parameters analysed 
with citrate and acetate.
Citrate Acetate p
pH pre 7.37 (0.04) 7.37 (0.06) NS
HCO3
– pre mmol/L 21.8 (2.3) 22.2 (0.3) NS
BE pre mmol/L –3.1 (2.5) –2.7 (2.2) NS
pCO2 pre mmHg 38.4 (4.7) 39.1 (5.8) NS
pO2 pre mmHg 78.7 (24.3) 72.8 (23.4) NS
sO2 pre % 90.3 (12.3) 88.8 (2.2) NS
Na pre mmol/L 139.1 (3.7) 138.8 (3.7) NS
K pre mmol/L 5.1 (0.7) 5.1 (0.6) NS
Mg pre mg/dl 2 (0.2) 2.1 (0.3) NS
Ca pre mg/dl 8.7 (0.6) 8.7 (0.6) NS
Cac pre mg/dl 8.6 (0.6) 8.6 (0.8) NS
Cai pre mmol/L 1.13 (0.09) 1.15 (0.08) NS
P pre mg/dl 4.2 (1.17) 4.03 (1) NS
PTH pre pg/ml 435.5 (316) 360.1 (252) NS
pH post 7.43 (0.04) 7.47 (0.05) 0.001
HCO3
- post mmol/L 24.7 (2.7) 27.3 (2.1) 0.0001
EB post mmol/L 0.4 (3.1) 3.7 (2.4) 0.0001
pCO2 post mmHg 36.7 (5.4) 38.4 (5.2) NS
pO2 post mmHg 79.6 (27.5) 72.5 (29) NS
sO2 post % 89.1 (17.2) 86.5 (18.3) NS
Na post mmol/L 136.9 (2.3) 136.6 (2.5) NS
K post* mmol/L 3.4 (0.2) 3.2 (0.2) 0.016
Mg post mg/dl 1.8 (0.2) 1.8 (0.2) NS
Ca post mg/dl 9.6 (0.6) 9.8 (0.5) NS
Cac post mg/dl 9.8 (0.8) 10.1 (0.7) 0.01
Cai post mmol/L 1.16 (0.05) 1.27 (0.06) 0.000
P post mg/dl 1.8 (0.5) 1.8 (0.4) NS
PTH post pg/ml 287.7 (194) 213.9 (289.7) NS
TAS pre mm Hg 150.3 (30.5) 147.5 (23.1) NS
TAD pre mm Hg 72.1 (14.1) 69.4 (11.7) NS
TAS post mm Hg 144.1 (20.2) 152.2 (28.4) NS
TAD post mm Hg 69.8 (14.3) 72.4 (11.5) NS
HCO3
–: bicarbonate; BE base excess; pCO2: partial pressure of 
carbon dioxide; pO2: partial pressure of oxygen (PO2), sO2: oxygen 
saturation; Na: sodium; K: potassium; Mg: magnesium; Ca: 
calcium; Cac: corrected calcium; Cai: ionic calcium; SBP: systolic 
blood pressure; DBP: diastolic blood pressure
*  Mean of total patients where a DF containing acetate was 
used with three K concentrations (1.5, 2 and 3 mmol/L) and DF 
containing citrate only 2 mmol/L. In the 12 (50%) patients with 
the same concentration (2 mmol/L), no differences were found 
in postdialysis K concentrations: 3.2 (0.2) and 3.4 (0.3) for acetate 
and citrate, respectively. For DF containing acetate with 1.5 and 3 
mmol/L of K, there were differences: 3.02 (0.1) vs. 3.4 (0.1) and 3.6 
(0.1) vs. 3.1 (0.1).
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favours calcification26. The article by Solis et al.27analyses the 
pH effect on calcif ication through two experimental 
approaches: the in vitro effect of uremic serum on plain mus-
cle cell calcification at different pH levels, and the in vivo 
effect of treatment with bicarbonate on nephrectomised rats. 
Its results suggest that extracellular alkalinisation promotes 
vascular calcification while acidification prevents it, both in 
cell cultures and uremic rats. The authors of this study have 
reproduced the situation faced by our dialysis patients, who 
usually have moderate metabolic acidosis and experience 
repeated episodes of sudden alkalinisation in dialysis ses-
sions.
There are certain situations in which preventing intradi-
alysis and postdialysis alkalosis is of special interest. 
Examples of these instances include patients with advanced 
chronic liver disease28, respiratory failure with extreme car-
bon dioxide retention, or those with clinical events that may 
worsen due to small modifications in acid-base balance 
occurring during dialysis and may even be life-threatening 
for the patient. The increase in pH may precipitate hepatic 
encephalopathy with severe liver failure, both acute and 
chronic, since it increases the NH3/NH4
+ ratio and the NH3 
passes through the blood-brain barrier more easily29. 
Respiratory failure and CO2 retention may worsen upon 
inducing metabolic alkalosis since respiratory compensation 
reduces the respiratory centre stimulation (lower respiratory 
amplitude and rate). These complications may be prevented 
by reducing bicarbonate concentration in the DF30 and/or 
using a DF such as citrate which produces less alkalinisation.
We have found only one publication that analyses the 
acute effect of citrate on acid-base balance. Higher alkalini-
sation was found during dialysis with citrate compared to 
acetate (7.38 to 7.50 and 21 to 29.2 mmol/L vs. 7.39 to 7.45 and 
22.4 to 24.3 for values of pH and bicarbonate with DF contain-
ing citrate and acetate, respectively)31. Our study shows that 
DF containing citrate produces less alkalaemia than acetate, 
shown by the differences in postdialysis gasometric param-
eters (pH, HCO3- and BE). It is important to consider that 
sodium and bicarbonate conductivities were kept stable. In 
addition, bicarbonate conductivity is individualised in our 
unit, and our goal is to achieve predialysis bicarbonate values 
> 18 mmol/L and postdialysis bicarbonate values < 28 mmol/L. 
We believe that the difference found may be even higher in 
units where bicarbonate does not meet each patient’s needs. 
Therefore, in our study, where the bicarbonate conductivity 
range is between 26 and 34 mmol/L, patients on dialysis with 
acetate showed a slight postdialysis alkalaemia, only three 
(12.5%) patients showed HCO3- levels greater than 30 mmol/L 
and no alkalaemia was observed with DF containing citrate 
(mean values of pH 7.43, HCO3- 24.7 mmol/L and BE 0.4). No 
patients showed HCO3- values greater than 30 mmol/L. 
Differences were kept in all used conductivity ranges, with 
no differences among them (results not shown).
The second result we would like to highlight is related to 
postdialysis calcaemia. Most studies analysing the effect of 
citrate on calcium-phosphorus metabolism have observed a 
reduction in Cai levels and an increase in PTH
17. With the 
calcium concentration used in the DF containing citrate, 
which was 0.15 mmol/L greater than that of acetate, we 
the rest of the analysed postdialysis values. Despite increas-
ing Ca concentration in the bath, the postHD Cai values were 
lower in patients who underwent dialysis with citrate, with 
no changes in PTH.
Results were also analysed according to technique (HD vs. 
HDF), and no statistically significant differences were found 
in the analysed parameters. No differences were found when 
we compared patients on HDF with infusion volumes higher 
or lower than 27 L either.
Regarding K, the concentration used was only the same 
with both DF in 12 (50%) patients (2 mmol/L), and no differ-
ences were found in postdialysis K concentrations: 3.2 (0.2) 
and 3.4 (0.3) mmol/L for acetate and citrate, respectively. 
Differences were found, however, in postdialysis potassium 
concentrations in total patients (Table 3) and, as expected, 
between the DF containing acetate with 1.5 mmol/L of K and 
the DF containing citrate with 2 mmol/L of K: 3.05 (0.1) vs. 3.48 
(0.1), respectively.
As far as efficacy is concerned, no differences were found 
with DF containing citrate and acetate, respectively: Kt 58.8 
(9.2) vs. 61.6 (6.8) L.
Finally, although no differences were found in postdialysis 
systolic and diastolic BP values with either DF (Table 2), there 
were differences in the number of symptomatic hypotension 
episodes. There were three symptomatic hypotension cases 
(6.2%) out of the total of sessions (48), and in the three cases 
a DF containing acetate was being used (12.5%). No hypoten-
sion episode was observed in the 24 sessions performed with 
citrate (0%). There were no differences in mean ultrafiltration 
rates in either group: 1849 (884) vs. 1904 (847) mL for citrate 
and acetate, respectively.
Discussion
The main result from our study is that dialysis with citrate 
provides better control of postdialysis acid-base balance than 
acetate by decreasing/avoiding postdialysis alkalaemia.
Acute alkalaemia induced by the addition of bicarbonate 
during dialysis is an issue which has considerable clinical 
significance. It has been related to important adverse effects, 
such as hemodynamic instability18,19,20, cardiac arrhythmia, 
paraesthesia/cramps21, reduced cerebral blood flow, respira-
tory distress,22,23headache, and a procalcifying effect. Finally, 
a higher bicarbonate concentration in the dialysis fluid has 
also been associated with increased mortality24.
The greater cardiac excitability is explained by several 
mechanisms, among which we could mention the effect met-
abolic alkalosis has on transcellular potassium redistribution. 
The increase in bicarbonate concentration favours potassium 
redistribution to the intracellular space, which may cause a 
more sudden decrease in the potassium levels during dialysis 
and precipitate cardiac arrhythmias25. The bicarbonate con-
ductivity of DF and plasma bicarbonatemia have been asso-
ciated with an increase in QT interval in postdialysis 
electrocardiographies, an effect which may probably be medi-
ated by the sudden decrease in both K and Cai.
The acid-base balance also plays a relevant role in the reg-
ulation of calcium deposits in blood vessels, so alkalosis 
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contribute to the increase in plasma bicarbonate concentra-
tion between 2 and 8 mEq/L, which may contribute to the 
development of postdialysis alkalosis. This fact led the Food 
and Drug Administration to write a communication warning 
physicians about the impact both acetate and other alkali 
sources have on bicarbonate prescription in dialysis37, and 
the risks of alkalosis induced by it. The way and period of time 
in which these acids are metabolised will have an impact on 
postdialysis acid-base balance values. The citrate-acetate con-
centration ratio we have used in the DF is 3/1 (3 mmol of ace-
tate and 1 mmol of citrate per litre). Although it may be 
considered that this could partially explain the results, this 
is not the case because each metabolised citrate molecule is 
equivalent to the generation of three bicarbonate molecules. 
Meanwhile, in acetate metabolism there is a stoichiometric 
generation of bicarbonate, due to equimolar consumption of 
a proton when it is activated by the Acetyl CoA synthetase to 
make Acetyl CoA. Therefore, 1 mmol/L of citrate and 3 mmol/L 
of acetate, upon being metabolised by the body, should theo-
retically generate a similar amount of bicarbonate. For this 
reason, it is not considered necessary to modify the bicarbon-
ate level prescribed when changing from a DF with 3-4 
mmol/L to a DF with 1 mmol/L of citrate. So, we should resort 
to chemistry to explain this: citrate is the base of citric acid, 
a weak organic acid, whose dominating form at physiological 
pH is trivalent citrate C3H5 (COO)
3-, of MW 189 D and a half-life 
of 30 to 60 minutes. Its metabolism is mainly hepatic and also 
muscular: citrate enters the cell through transport proteins, 
then it moves into the mitochondrion, where it is converted 
into isocitrate during the Krebs cycle and, subsequently, into 
alpha-ketoglutarate, which is metabolised to generate bicar-
bonate and energy. Therefore, a fast conversion from citrate 
to bicarbonate takes place, but the main difference with ace-
tate lies in the fact that this metabolism is incomplete during 
dialysis, since hepatic and muscular metabolism partly occurs 
after the technique is completed. Moreover, there are patients 
with fast metabolisms and others with slow metabolisms, 
depending on their liver function and muscle mass, which are 
factors that should also be taken into account. In patients who 
receive a citrate infusion as regional anticoagulant therapy, 
the plasma citrate levels are of 1 mmol/L, and patients on HD 
show similar levels to those having a normal renal function38. 
This is unlike patients with liver failure, in whom citrate 
clearance is reduced by 50%39. Another possible explanation 
for the lower alkalosis with citrate may be due to the different 
composition of both DF (Table 1), with components showing 
a different ionic strength.
Thus, to answer the foregoing question, the ideal bicarbon-
ate conductivity with which patients should undergo dialysis 
has not been precisely determined. This value will depend on 
patient-related factors (predialysis bicarbonate concentration, 
hydrogen ion generation, bicarbonate distribution space, etc.) 
and dialysis-related factors (bath bicarbonate concentration, 
type of technique, frequency, ultrafiltration, blood flow and 
bath f low, etc.), among others. In light of our results, we 
should probably also add to these the type and concentration 
of acid used in the DF.
The main restriction of our study is that the number of 
patients included is small, but the crossover design enables 
observed no clinical or analytical hypocalcaemia and postdi-
alysis values of both Cac and Cai were significantly lower 
using the DF containing citrate compared to acetate. 
Furthermore, with both DF at the used calcium concentra-
tions, postdialysis values of Cac and Cai were greater than 
those obtained before dialysis. This result is even more 
important if we consider how changes in pH modify Cai
32. 
Hydrogen ions displace Ca from albumin, so a reduction of 0.1 
in pH increases the Cai concentration by 0.1 mEq/L, approxi-
mately, while alkalosis reduces free Ca and increases Ca bind-
ing to albumin. In our case, the postdialysis pH was higher in 
the dialysis conducted with acetate; had this not been true, 
the difference would have been even higher. In fact, no dif-
ferences were found in postdialysis non-corrected Ca values, 
but there were differences in the corrected ones (9.8 and 10.1 
mg/dL with citrate and acetate, respectively).
We have not found higher clearance with the DF containing 
citrate, although other authors have16. This finding has been 
related to the local anticoagulant effect of citrate, which 
would imply a lower thrombogenicity and, therefore, a lower 
loss of useful surface area of the dialyser and, as a result, of 
dialysis efficacy. We have analysed the effect of both DF on 
coagulation in 12 patients by means of a visual classification 
of the status of the lines, chambers and dialyser (results not 
shown), and no differences were found either.
Finally, based on the higher hemodynamic stability 
described with citrate15, we have found no differences in 
blood pressure (BP), but we have found differences in the inci-
dence of symptomatic hypotension episodes. Although the 
number of hypotension cases found was very low (in only 3 
out of the 48 sessions was there hypotension [6.2%]), in the 
three cases it occurred using a DF containing acetate. No 
hypotensive episodes were observed in the 24 sessions per-
formed with citrate (12.5 vs. 0%). It is worth mentioning that 
our incidence of hypotension is much lower than that 
reported in literature, ranging from 15 to 60%33,34. This result 
may also be explained by the known vasodilator effect of ace-
tate, due to a lower bicarbonatemia found with citrate, since 
a direct relationship between bicarbonate concentration in 
DF and hemodynamic stability has been described19. The 
higher hemodynamic stability may also be the result of higher 
sodium [Na] concentration in the DF at an equal conductivity 
due to a modification in the relationship between the two (Na 
and conductivity). We have undisclosed data supporting this 
hypothesis.
There is no doubt that individualisation of the dialysis 
therapy should also include the bicarbonate concentration in 
the bath35. But, considering the results obtained in our study, 
should such individualisation be extended to the type of acid 
used? We should first consider that the bicarbonate concen-
tration we set underestimates the actual concentration, since 
part of the acetate or citrate contained in the DF will then 
convert into bicarbonate. Both citrate and acetate transfer to 
plasma depend on the type of dialysis, clearance and treat-
ment time, among other factors. As a result, the plasma citrate 
level increases <0.1 mmol/L at 0.2 to 0.3 mmol/L36during dial-
ysis with DF containing 1 mmol/L of citrate, while the acetate 
level increases from 0.2 to 0.5 mmol/L with a DF containing 4 
mmol/L of acetate8. Once metabolised, acetate and citrate 
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Martínez Miguel P, Cofre R. Clinical and analytical changes in 
hemodiálisis without acetate. Nefrología. 2007;27:742-8.
 9.  Steckiph D, Bertucci A, Petrarulo M, Baldini C, Calabrese 
G, Gonelle M, et al: Calcium mass balances in online 
hemodiafiltration (HDF) using citrate containing acetate-
free and regular dialysis concentrates. Abstract ERA-EDTA 
Congress 2013. 
10.  Sands JJ, Kotanko P, Segal JH, Ho CH, Usvat L, Young A. 
Effects of citrate acid concentrate on heparin requirements 
and hemodialysis adequacy: a multicenter, prospective 
noninferiority trial. Blood Purif. 2012;33:199-204. 
11.  Gabutti L, Lucchini B, Marone C, Alberio L, Burnier M. Citrate 
vs acetate based dialysate in bicarbonate haemodialysis: 
consequences on haemodynamics,coagulation, acid-base 
status, and electrolytes. BMC Nephrol. 2009;10:1-11. 
12.  Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased 
efficiency of hemodialysis with citrate dialysate: A prospective 
controlled study. Clin J Am Soc Nephrol. 2009;4:1459-64.
13.  Bryland A, Wieslander A, Carlsson O, Hellmark T, Godaly G. 
Citrate treatment reduces endothelial death and inflammation 
under hyperglycaemic conditions. Diab Vasc Dis Res. 
2012;9:42-51.
14.  Matsuyama K, Tomo T, Kadota J. Acetate-free blood purification 
can impact improved nutritional status in hemodialysis 
patients. J Artif Organs. 2011;14:112-9. 
15.  Daimon S, Dan K, Kawano M. Comparison of acetate-free 
citrate hemodialysis and bicarbonate hemodialysis regarding 
the effect of intra-dialysis hypotension and post-dialysis 
malaise. Ther Apher Dial. 2011;15:460-5. 
16.  Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased 
efficiency of hemodialysis with citrate dialysate: a prospective 
controlled study. Clin J Am Soc Nephrol. 2009;4:1459-64.
17.  Grundström G, Christensson A, Alquist M, Nilsson LG, 
Segelmark M. Replacement of acetate with citrate in dialysis 
fluid: a randomized clinical trial of short term safety and fluid 
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the comparison between each patient and himself/herself, 
thus reinforcing the results. A second restriction is that the 
order of use of each acid in the DF has not been randomised. 
Even so, by analysing its acute effect, we think the impact of 
this randomisation would be minimal. Finally, the study has 
been conducted at a single hospital, but we believe the results 
may be valid for other centres with similar dialysis condi-
tions.
It would have been interesting to measure citrate concen-
trations and acid-base balance parameters, not only postdi-
alysis but also in the interdialysis period, in order to elaborate 
more on the metabolism mechanisms of both acids. This 
study opens the doors to future research analysing the clin-
ically significant differences in patients with long-term treat-
ment with DF containing citrate.
Conclusions
The results of this article show that dialysis with citrate pro-
vides better control of postdialysis acid-base balance and 
decreases/avoids postdialysis alkalaemia. The lower postdi-
alysis alkalaemia, together with a lower increase in calcae-
mia, support a less calcifying profile of the DF containing 
citrate.
This finding is of special interest in patients with factors 
predisposing to arrhythmia and those with respiratory fail-
ure, carbon dioxide retention, calcifications and advanced 
liver disease.
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